At the last check on Thursday, Cardinal Health Inc.’s (NYSE:CAH) stock was up $0.11, moving up 0.12 percent to $89.48. The average number of shares traded per day over the past five days has been 1,897,713 shares. 4 times new highs have been achieved over the past 5 days, with a $1.78 gain in that time frame. In the last twenty days, the average volume was 2,027,078, while in the previous 50 days, it was 2,145,893.
Since last month, CAH stock rose 4.63%. Shares of the company fell to $85.11 on 08/23/23, the lowest level in the past month. A 52-week high of $95.45 was reached on 08/15/23 after having rallying from a 52-week low of $64.99. Since the beginning of this year, CAH’s stock price has risen by 16.40% or $12.61, and marked a new high 29 times. However, the stock has declined by -6.25% since its 52-week high.
CAH stock investors should be aware that Cardinal Health Inc. (CAH) stock had its last reported insider trading activity 24 days ago on Aug 28. WEITZMAN DEBORAH, the CEO, Pharmaceutical Segment of the company, disposed of 6,712 shares for $89.81 on Aug 28. It resulted in a $602,805 divestment by the insider. Scherer Mary C. sold 20,695 shares at an average price of $86.27 on Aug 18. The insider now owns 10,649 shares following the transaction. On Aug 17, CEO, Medical Segment Mason Stephen M sold 37,500 shares at $87.32 apiece. The transaction was valued at $3,274,642.
Valuation Metrics
Right now, Cardinal Health Inc. (CAH) has a P/E ratio of about 90.29. The stock’s beta is 0.79.
The latest dividend of $0.5006 per share was paid out, remained unchanged from last year’s $0.5006.
Financial Health
In the three months ended June 29, Cardinal Health Inc.’s quick ratio stood at 0.50, while its current ratio was 1.00, showing that the company is not able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 3.40% percent. In the year ended June 29, operating margins totaled 0.40%. Based on annual data, CAH earned $6.89 billion in gross profit and brought in $205.01 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 19.00%. Return on equity (ROE) for the past 12 months was -11.50%.
In Cardinal Health Inc.’s quarter-end financial report for June 29, it reported total debt of $3.91 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. CAH’s revenue rose 11.88% to $50.49 billion during the quarter, while net income inched up to $53.45 billion. While analysts expected Cardinal Health Inc. to report $1.49 quarterly earnings, the actual figure was $1.55 per share, beating the consensus estimate by 4.00%. During the quarter, the company generated $313.0 million in EBITDA. The liabilities of Cardinal Health Inc. were 46.27 billion at the end of its most recent quarter ended June 29, and its total debt was $5.27 billion. The value of shareholders’ equity is $250.68 million.
Technical Picture
This quick technical analysis looks at Cardinal Health Inc.’s (CAH) price momentum. With a historical volatility rate of 11.79%, the RSI 9-day stood at 59.57% on 20 September.
With respect to its five-day moving average, the current Cardinal Health Inc. price is up by +2.03% percent or $1.78. At present, CAH shares trade +4.81% above its 20-day simple moving average and +8.99% percent above its 100-day simple moving average. However, the stock is currently trading approximately -4.37% below its SMA50 and +10.63% above its SMA200.
Stochastic coefficient K was 72.48% and Stochastic coefficient D was 56.16%, while ATR was 1.20. Given the Stochastic reading of 86.90% for the 14-day period, the RSI (14) reading has been calculated as 53.87%. As of today, the MACD Oscillator reading stands at 0.44, while the 14-day reading stands at 0.72.
Analyst Ratings
Cardinal Health Inc. downgraded its rating on Cardinal Health Inc. (NYSE: CAH) to an In-line in a note to investors on July 10, 2023. The analysts firm previously had an Outperform rating on the stock.
